
    
      This study is designed to evaluate and compare the rotigotine pharmacokinetic profile of a
      single 28 mg intramuscular dose of LY03003 Formulation A and LY03003 Formulation B. The
      secondary objective of the trial is to evaluate the safety and tolerability of LY03003
      Formulation A and LY03003 Formulation B following a single 28 mg IM dose administered to
      patients with Parkinson's Disease.
    
  